scholarly journals Use of Acellular Dermal Matrix in Reconstructive Surgery: A Review

2021 ◽  
Vol 18 (3) ◽  
pp. 56-60
Author(s):  
Ji Won Park ◽  
Soo Wook Chae ◽  
Byung Min Yun

In recent decades, tissue engineering advances have led to more skin substitutes becoming available. Acellular dermal matrix, initially developed for use in the treatment of full-thickness burns, is made by removing the cellular components from the dermis collected from donated bodies or animals. This class of scaffold is used to replace skin and soft tissue deficiencies in a variety of fields, including breast reconstruction, abdominal wall reconstruction, and burn treatment. Herein, we provide a detailed review of the clinical applications of acellular dermal matrix.

2018 ◽  
Vol 375 (3) ◽  
pp. 709-721 ◽  
Author(s):  
Mohamad Javad Mirzaei-parsa ◽  
Hossein Ghanbari ◽  
Behnam Alipoor ◽  
Amirhossein Tavakoli ◽  
Mohammad Reza H. Najafabadi ◽  
...  

2020 ◽  
Vol 231 (4) ◽  
pp. S223
Author(s):  
Malke Asaad ◽  
Donald Peter Baumann ◽  
Sahil Kuldip Kapur ◽  
Alexander F. Mericli ◽  
Jun Liu ◽  
...  

2019 ◽  
Vol 85 (9) ◽  
pp. 1056-1060
Author(s):  
Rachel E. Lewis ◽  
Emily A. Towery ◽  
Sneha G. Bhat ◽  
Andrew J. Ward ◽  
Robert E. Heidel ◽  
...  

Skin substitutes have shown success in complex wound reconstruction. We evaluate the use of a human acellular dermal matrix (ADM) as a viable alternative to autologous skin grafting for defects secondary to skin cancer excision. An institutional review board–approved, retrospective review of ADM-reconstructed defects secondary to skin cancer excision between 2012 and 2018 was conducted. ADM was indicated in patients with preclusive factors for general anesthesia, protracted procedure time, reluctance for additional donor site wound, and personal choice. We reviewed defect characteristics, healing time, postoperative outcomes, and patient demographics. The 228 participants (151 males, 77 females) had a median age of 72 years (range, 29–95 years), with melanoma diagnosed in 113 (49.6%), squamous cell carcinoma in 61 (26.8%), and basal cell carcinoma in 28 (12.2%) patients. The median interval to complete epidermal coverage was 42 days, with graft failure evident in six patients (2.6%). ADM is a viable, low-morbid alternative for reconstruction of defects secondary to skin cancer excision, with no donor site morbidity. With exception to complete healing time, outcomes are similar to those of autologous grafting.


2017 ◽  
Vol 224 (3) ◽  
pp. 341-350 ◽  
Author(s):  
Patrick B. Garvey ◽  
Salvatore A. Giordano ◽  
Donald P. Baumann ◽  
Jun Liu ◽  
Charles E. Butler

Sign in / Sign up

Export Citation Format

Share Document